No Data
Trending Stocks Today | Polyrizon Shoots up 217.71%
Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating
Earnings Call Summary | Summit Therapeutics(SMMT.US) Q1 2025 Earnings Conference
Summit Therapeutics Outlines Ivonescimab Progress With Key Phase III Data Expected Mid-2025
Summit Therapeutics Non-GAAP EPS of -$0.07 Beats by $0.02
Summit Therapeutics Q1 Loss Widens; Cash Equivalents Drop